drugset / Trial / NCT07275853
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
Phase 1
Not yet recruiting
30 enrolled
TCRx Therapeutics Co.Ltd
Chinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Timeline
- Start
- 2025-12-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KXV01 TCR Lentinvivo | Unknown | — | — |